Search clinical trials for: SPD476, MMX™ mesalazine, 4.8g extended release tablet

Total 10 results

Shire

Completed

Prevention of Recurrence of Diverticulitis (PREVENT2)

Diverticulitis

United States, Italy, Germany, Canada, Brazil, Romania, Netherlands, Finland, South Africa, Hungary
Shire

Completed

Prevention of Recurrence of Diverticulitis (PREVENT1)

Diverticulitis

New Zealand, United States, United Kingdom, Sweden, Australia, Israel, India, Spain, Colombia, Argentina, France
Shire

Completed

Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Belgium
Shire

Completed

Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476

Colitis, Ulcerative

Belgium
Reckitt Benckiser LLC

Completed

Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion

Healthy Subjects
Duke University

Terminated

Persistent Postpartum Hypertension Pilot Trial

Hypertension in Pregnancy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg

Healthy

United States
Wayne State University

Completed

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (BOS)

Heroin Dependence | Opioid Use Disorder

United States
Vanderbilt University Medical Center
Veloxis Pharmaceuticals

Enrolling by invitation

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Lung Transplant; Complications

United States
Simon Tremblay, PharmD, PhD
Veloxis Pharmaceuticals

Unknown

Veloxis de Novo Kidney Transplant ECSWD

Kidney Transplantation | Immunosuppression

United States

3

Subscribe